JCR Pharmaceuticals Co., Ltd.(JP:4552)
¥499.00+6.00 (+1.22%)
JP:4552
JCR Pharmaceuticals Co., Ltd. earnings date
¥499.00
At close:+6.00 (+1.22%)
Want to see JP:4552 full AI Analyst Report?
JCR Pharmaceuticals Co., Ltd. (4552) Q2 2022 Earnings Report
1 Followers
JP:4552 Q2 2022 EPS Results
- Actual EPS
- -JPY 3.29
- Consensus EPS
- JPY 615.56
- Beat/Miss
- Missed by -JPY 618.85
- One Year Ago EPS
- JPY 62.26
JP:4552 Q2 2022 Revenue Results
- Actual Revenue
- JPY 5.97B
- Expected Revenue
- JPY 1.30T
- Beat/Miss
- Missed by -JPY 1.29T
- YoY Revenue Growth
- -67.82%
Earnings Announcement Details
- Quarter
- Q2 2022
- Date
- 10/26/2022
- Time
- TBA
- Conference Call
- Wednesday, October 26, 2022
JP:4552 Upcoming Earnings
JCR Pharmaceuticals Co., Ltd.'s next earnings date is estimated for January 28, 2027, based on past reporting schedules.
Q2 2022 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2022 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2022 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4552 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 28, 2027 | 2026 (Q3) | -13.83- | 0.27 | ― | ― |
| Oct 29, 2026 | 2026 (Q2) | ―-16.03 | 18.51 | -186.60% (-34.54) | |
| Jul 30, 2026 | 2026 (Q1) | -11.27-15.64 | -4.48 | -249.11% (-11.16) | |
| May 13, 2026 | 2025 (Q4) | -6.633.57 | -33.8 | 110.56% (+37.37) | |
| Jan 28, 2026 | 2025 (Q3) | -1.070.27 | 0.9 | -70.00% (-0.63) | |
| Oct 30, 2025 | 2025 (Q2) | 20.3918.51 | -7.14 | 359.24% (+25.65) | |
| Jul 30, 2025 | 2025 (Q1) | 4.36-4.48 | 1.61 | -378.26% (-6.09) | |
| May 13, 2025 | 2024 (Q4) | -53.70-33.80 | 2.78 | -1315.83% (-36.58) | |
| Jan 31, 2025 | 2024 (Q3) | 11.180.90 | -0.75 | 220.00% (+1.65) | |
| Oct 30, 2024 | 2024 (Q2) | 13.72-7.14 | 29.19 | -124.46% (-36.33) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

